Promimic Secures Funding to Support U.S. Market Entry

Promimic secured funding of SEK 23.8MM (~US $3.2MM) from new and existing investors to establish commercial operations in the U.S.—specifically, Austin, Texas.

CEO Ulf Brogren will assemble a regional sales team to serve orthopaedic and dental implant markets with products enhanced by HAnano Surface coating technology. Production and development will remain in Sweden.

Promimic’s first FDA 510(k) clearance was granted in 2011 for a dental implant using HAnano Surface; a spinal implant using the technology is under review. In 1Q16, the company signed a license agreement whereby Danco invested in a production line for the HAnano Surface process, and Danco is the preferred process partner for Promimic for U.S. and China medical implant markets.

The HAnano Surface is 20 nanometers thin and has demonstrated the ability to improve and accelerate osseointegration in >20 pre-clinical studies. Through its wet chemical process, it can be applied to almost any implant material and shape to support integration with bone.

Source: Promimic


The nanotechnology industry is growing rapidly, with reports claiming varying annual revenues between $300 billion to $3 trillion. The projected evolution of nanotechnology in orthopaedics includes surface treatments, biologics, antimicrobial components and sensors. The main goals are to develop an implant that the body responds to faster and to develop an implant that decreases the chance for infection. While most companies are focused on its use in spine, an advantage of nanotechnology is that it can be widely used throughout the body.

Learn more about the technology’s developing role in “The Future of Nanotechnology in Orthopaedics.”


 

 

RELATED ARTICLES



CONTACT BONEZONE

 

CONTACT BONEZONE